Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Eplontersen sodium by AstraZeneca for Familial Amyloid Cardiomyopathy: Likelihood of Approval
Eplontersen sodium is under clinical development by AstraZeneca and currently in Phase III for Familial Amyloid Cardiomyopathy. According to GlobalData,...